 |
|
One-Year Results of Excimer Laser Photorefractive Keratectomy for Low to Moderate Myopia
Srinivas Dutt, MD;
Roger F. Steinert, MD;
Michael B. Raizman, MD;
Carmen A. Puliafito, MD
Arch Ophthalmol. 1994;112(11):1427-1436.
Abstract
| |
Objective
Excimer photorefractive keratectomy is a promising method to reduce myopia. We evaluated the effectiveness, predictability, stability, and safety of photorefractive keratectomy performed by two surgeons at a single site with a 1-year follow-up.
Methods
An excimer laser (Summit Excimed UV200, Summit Technology, Waltham, Mass) was used to treat 47 eyes. Preoperative uncorrected visual acuity averaged 20/277 and ranged from 20/60 to 20/500. Spherical equivalent averaged –3.9 diopters and ranged from –1.5 to –6.1 D.
Results
One year postoperatively, best corrected visual acuity averaged 20/13 and ranged from 20/10 to 20/20. No patients lost any of best corrected visual acuity. The uncorrected visual acuity at 1 year averaged 20/20 and ranged from 20/10 to 20/200. Ninety-four percent of eyes had an uncorrected visual acuity of 20/40 or better; 83%, 20/25 or better; and 74%, 20/20 or better. An initial hyperopic overcorrection is followed by gradual regression to emmetropia during a 12-month period. Refractive spherical equivalent averaged 0.44 D and ranged from –3 to +2.6 D at 1 year. The proportion of eyes within I D of emmetropia was 80% at 1 year. The most significant shifts in refraction occurred between the first and second months, but small shifts occurred up to 12 months. Subgrouping the results according to age revealed a significantly greater effect with larger residual hyperopia in those older than 40 years. Patient satisfaction with the procedure was high.
Conclusion
During a 1-year period, excimer photorefractive keratectomy appears to be an effective, predictable, stable, and safe method to reduce myopia. Age may play a role in the effectiveness of the procedure, with greater hyperopia resulting in those older than 40 years.
Author Affiliations
From the New England Eye Center, Tufts University School of Medicine (Drs Dutt, Raizman, and Puliafito) and the Center for Eye Research, Ophthalmic Consultants of Boston (Mass) (Dr Steinert). Dr Steinert is the phase III Medical Monitor for Summit Technology. Dr Puliafito is a paid consultant to Summit Technology. Drs Dutt and Raizman have no commercial proprietary interest in the Summit excimer laser or Summit Technology, Waltham, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Age-related differences in the normal human cornea: a laser scanning in vivo confocal microscopy study
Niederer et al.
Br J Ophthalmol 2007;91:1165-1169.
ABSTRACT
| FULL TEXT
The usefulness of Vistech and FACT contrast sensitivity charts for cataract and refractive surgery outcomes research
Pesudovs et al.
Br J Ophthalmol 2004;88:11-16.
ABSTRACT
| FULL TEXT
Analysis of glycosaminoglycans in rabbit cornea after excimer laser keratectomy
Kato et al.
Br J Ophthalmol 1999;83:609-612.
ABSTRACT
| FULL TEXT
Should Laser Refractive Surgery Be Delayed?; There Is No Benefit to Deferring Laser Refractive Surgery
Maloney and Faktorovich
Arch Ophthalmol 1998;116:669-672.
FULL TEXT
Aging and the cornea
FARAGHER et al.
Br J Ophthalmol 1997;81:814-817.
FULL TEXT
Influence of patient age on refraction and corneal haze after photorefractive keratectomy
Hefetz et al.
Br J Ophthalmol 1997;81:637-638.
ABSTRACT
| FULL TEXT
Visual Performance After Photorefractive Keratectomy: A Prospective Study
Verdon et al.
Arch Ophthalmol 1996;114:1465-1472.
ABSTRACT
Overcorrection After Excimer Laser Treatment of Myopia and Myopic Astigmatism
Vajpayee et al.
Arch Ophthalmol 1996;114:252-256.
ABSTRACT
Fortnightly Review: Treating myopia with the excimer laser: the present position
Gartry
BMJ 1995;310:979-985.
ABSTRACT
| FULL TEXT
|
